NOVEL-1st: A Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

▪ Background Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), has been approved for the treatment of patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) globally, including Taiwan. However, the real-world evidence regar...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.2-3
Hauptverfasser:	Wen-Li, Hwang, Chen, Tsung-Chih, Lin, Shyuann-Yuh, Chang, Ming-Chih, Hsiao, Pei-Ching, Bai, Li-Yuan, Kuo, Ching-Yuan, Chen, Yeu-Chin, Liu, Ta-Chih, Gau, Jyh-Pyng, Wang, Po-Nan, Chen, Chieh-Wen, Lee, Yee-Ming, Ku, Fan-Chen, Tang, Jih-Luh
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!